PROFILPELAJAR.COM

Droperidol
Clinical data
Pronunciation	/droʊˈpɛrIdɔːl/
Pregnancy; category	AU: C; ;
Routes of; administration	Intravenous, Intramuscular
Drug class	Typical antipsychotic
ATC code	N05AD08 (WHO) ;
Legal status
Legal status	AU: S4 (Prescription only); BR: Class C1 (Other controlled substances); UK: POM (Prescription only); US: WARNINGRx-only;
Pharmacokinetic data
Metabolism	Hepatic
Elimination half-life	2.3 hours
Identifiers
	IUPAC name 3-[1-[4-(4-fluorophenyl)-4-oxobutyl]-3,6-dihydro-2H-pyridin-4-yl]-1H-benzimidazol-2-one;
CAS Number	548-73-2;
PubChem CID	3168;
DrugBank	DB00450;
ChemSpider	3056;
UNII	O9U0F09D5X;
KEGG	D00308;
ChEMBL	ChEMBL1108 ;
CompTox Dashboard (EPA)	DTXSID6022973 ;
ECHA InfoCard	100.008.144
Chemical and physical data
Formula	C22H22FN3O2
Molar mass	379.435 g·mol−1
3D model (JSmol)	Interactive image; Interactive image;
	SMILES c1ccc2c(c1)nc(n2C3=CCN(CC3)CCCC(=O)c4ccc(cc4)F)O; ; Fc1ccc(cc1)C(=O)CCCN2CC=C(CC2)N3c4ccccc4NC3=O;
	InChI InChI=1S/C22H22FN3O2/c23-17-9-7-16(8-10-17)21(27)6-3-13-25-14-11-18(12-15-25)26-20-5-2-1-4-19(20)24-22(26)28/h1-2,4-5,7-11H,3,6,12-15H2,(H,24,28); Key:RMEDXOLNCUSCGS-UHFFFAOYSA-N;

Droperidol /droʊˈpɛrɪdɔːl/ (Inapsine, Droleptan, Dridol, Xomolix, Innovar [combination with fentanyl]) is an antidopaminergic drug used as an antiemetic (that is, to prevent or treat nausea) and as an antipsychotic. Droperidol is also often used as a rapid sedative in intensive-care treatment, and where "agitation aggression or violent behavior"^[4] are present.^[5]^[6]

History

Discovered at Janssen Pharmaceutica in 1961, droperidol is a butyrophenone which acts as a potent D₂ (dopamine receptor) antagonist with some histamine and serotonin antagonist activity.^[7]

Medical use

It has a central antiemetic action and effectively prevents postoperative nausea and vomiting in adults using doses as low as 0.625 mg.

For treatment of nausea and vomiting, droperidol and ondansetron are equally effective; droperidol is more effective than metoclopramide.^[8] It has also been used as an antipsychotic in doses ranging from 5 to 10 mg given as an intramuscular injection, generally in cases of severe agitation in a psychotic patient who is refusing oral medication. Its use in intramuscular sedation has been replaced by intramuscular preparations of haloperidol and olanzapine. Some practitioners recommend the use of 0.5 mg to 1 mg intravenously for the treatment of vertigo in an otherwise healthy elderly patients who have not responded to Epley maneuvers.

Black box warning

In 2001, the FDA changed the labeling requirements for droperidol injection to include a Black Box Warning, citing concerns of QT prolongation and torsades de pointes. The evidence for this is disputed, with 9 reported cases of torsades in 30 years and all of those having received doses in excess of 5 mg.^[9] QT prolongation is a dose-related effect,^[10] and it appears that droperidol is not a significant risk in low doses. A study in 2015 showed that droperidol is relatively safe and effective for the management of violent and aggressive adult^[11] patients in hospital emergency departments in doses of 10mg and above and that there was no increased risk of QT prolongation and torsades de pointes.

Side effects

Dysphoria, sedation, hypotension resulting from peripheral alpha adrenoceptor blockade, prolongation of QT interval which can lead to torsades de pointes, and extrapyramidal side effects such as dystonic reactions/neuroleptic malignant syndrome.^[12]

References

^ "FDA-sourced list of all drugs with black box warnings (Use Download Full Results and View Query links.)". nctr-crs.fda.gov. FDA. Retrieved 22 Oct 2023.
^ "Prescription medicines: registration of new generic medicines and biosimilar medicines, 2017". Therapeutic Goods Administration (TGA). 21 June 2022. Retrieved 30 March 2024.
^ Anvisa (2023-03-31). "RDC Nº 784 - Listas de Substâncias Entorpecentes, Psicotrópicas, Precursoras e Outras sob Controle Especial" [Collegiate Board Resolution No. 784 - Lists of Narcotic, Psychotropic, Precursor, and Other Substances under Special Control] (in Brazilian Portuguese). Diário Oficial da União (published 2023-04-04). Archived from the original on 2023-08-03. Retrieved 2023-08-16.
^ Edge R, Argáez C. Droperidol for Agitation in Acute Care [Internet]. Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2021 Jan. Available from: https://www.ncbi.nlm.nih.gov/books/NBK571530/
^ Perkins J, Ho JD, Vilke GM, DeMers G (July 2015). "American Academy of Emergency Medicine Position Statement: Safety of Droperidol Use in the Emergency Department". The Journal of Emergency Medicine. 49 (1): 91–97. doi:10.1016/j.jemermed.2014.12.024. PMID 25837231.
^ Klein LR, Driver BE, Horton G, Scharber S, Martel ML, Cole JB (May 2019). "Rescue Sedation When Treating Acute Agitation in the Emergency Department With Intramuscular Antipsychotics". The Journal of Emergency Medicine. 56 (5): 484–490. doi:10.1016/j.jemermed.2018.12.036. PMID 30745194. S2CID 73436531.
^ Peroutka SJ, Synder SH (December 1980). "Relationship of neuroleptic drug effects at brain dopamine, serotonin, alpha-adrenergic, and histamine receptors to clinical potency". The American Journal of Psychiatry. 137 (12): 1518–1522. doi:10.1176/ajp.137.12.1518. PMID 6108081.
^ Domino KB, Anderson EA, Polissar NL, Posner KL (June 1999). "Comparative efficacy and safety of ondansetron, droperidol, and metoclopramide for preventing postoperative nausea and vomiting: a meta-analysis". Anesthesia and Analgesia. 88 (6): 1370–1379. doi:10.1213/00000539-199906000-00032. PMID 10357347.
^ Kao LW, Kirk MA, Evers SJ, Rosenfeld SH (April 2003). "Droperidol, QT prolongation, and sudden death: what is the evidence?". Annals of Emergency Medicine. 41 (4): 546–558. doi:10.1067/mem.2003.110. PMID 12658255.
^ Lischke V, Behne M, Doelken P, Schledt U, Probst S, Vettermann J (November 1994). "Droperidol causes a dose-dependent prolongation of the QT interval". Anesthesia and Analgesia. 79 (5): 983–986. doi:10.1213/00000539-199411000-00028. PMID 7978420.
^ Calver L, Page CB, Downes MA, Chan B, Kinnear F, Wheatley L, et al. (September 2015). "The Safety and Effectiveness of Droperidol for Sedation of Acute Behavioral Disturbance in the Emergency Department". Annals of Emergency Medicine. 66 (3): 230–238.e1. doi:10.1016/j.annemergmed.2015.03.016. PMID 25890395.
^ Park CK, Choi HY, Oh IY, Kim MS (October 2002). "Acute dystonia by droperidol during intravenous patient-controlled analgesia in young patients". Journal of Korean Medical Science. 17 (5): 715–717. doi:10.3346/jkms.2002.17.5.715. PMC 3054934. PMID 12378031.